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Abstract
Background: Genetic loss-of-function variants (LoFs) associated with disease traits are increasingly recognized as
critical evidence for the selection of therapeutic targets. We integrated the analysis of genetic and clinical data from
10,511 individuals in the Mount Sinai BioMe Biobank to identify genes with loss-of-function variants (LoFs)
significantly associated with cardiovascular disease (CVD) traits, and used RNA-sequence data of seven metabolic
and vascular tissues isolated from 600 CVD patients in the Stockholm-Tartu Atherosclerosis Reverse Network
Engineering Task (STARNET) study for validation. We also carried out in vitro functional studies of several candidate
genes, and in vivo studies of one gene.
Results: We identified LoFs in 433 genes significantly associated with at least one of 10 major CVD traits. Next, we
used RNA-sequence data from the STARNET study to validate 115 of the 433 LoF harboring-genes in that their
expression levels were concordantly associated with corresponding CVD traits. Together with the documented
hepatic lipid-lowering gene, APOC3, the expression levels of six additional liver LoF-genes were positively associated
with levels of plasma lipids in STARNET. Candidate LoF-genes were subjected to gene silencing in HepG2 cells with
marked overall effects on cellular LDLR, levels of triglycerides and on secreted APOB100 and PCSK9. In addition, we
identified novel LoFs in DGAT2 associated with lower plasma cholesterol and glucose levels in BioMe that were also
confirmed in STARNET, and showed a selective DGAT2-inhibitor in C57BL/6 mice not only significantly lowered
fasting glucose levels but also affected body weight.
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Conclusion: In sum, by integrating genetic and electronic medical record data, and leveraging one of the world’s
largest human RNA-sequence datasets (STARNET), we identified known and novel CVD-trait related genes that may
serve as targets for CVD therapeutics and as such merit further investigation.
Keywords: Loss-of-function variant, Cardiovascular traits, Genetic association, Integrative data analysis, Target
identification and validation, Electronic Medical Records
Background
The delineation and association of loss-of-function vari-
ants (LoFs) with human diseases and phenotypic traits
continues to play an increasingly important role in the
discovery and validation of novel therapeutic targets.
Nonsense mutations in PCSK9 are associated with an
88% reduction in the risk of coronary heart disease
(CHD) [1]. While large clinical trials are ongoing [2],
current evidence suggests that PCSK9 inhibitors not
only lower LDL cholesterol, but also reduce cardiovascu-
lar events [3, 4]. In fact, in the recent published FOU-
RIER trial, the PCSK9 inhibitor Evolocumab used in
conjunction with background of statin therapy was
shown to significantly reduce the risk of cardiovascular
events as well as levels of plasma LDL cholesterol [5]. In
another example, LoF mutations in NPC1L1, encoding a
transporter involved in the absorption of dietary choles-
terol, are associated with reduced incidence of CHD [6],
and a small-molecule inhibitor of NPC1L1, ezetimibe,
was found to both lower plasma LDL levels and reduce
the risk of CHD events [7]. HMGCR, LDLR, and APOC3
are additional examples of genes with LoFs or other gen-
etic variants where carriers show lower levels of plasma
LDL or triglycerides and a reduced incidence of CHD [8,
9]. It is also well known that statin therapy targeting
HMGCR reduces risk of both primary and recurrent
CHD events [10]. Hence, the evidence that human gen-
etics may improve therapeutic target selection is mount-
ing and increasingly recognized. In fact, retrospective
analysis shows that for novel targets with human genetic
validation, the rate of success in clinical development is
increased twofold [11].
Besides the targeted analysis of human LoFs in candi-
date genes, several systematic surveys of LoFs [12, 13]
and their associations with clinical phenotypes [14–18]
have been performed including the recent DiscovEHR
study [19] where the distribution and clinical impact of
LoFs in 50,726 whole exomes were investigated. A com-
mon theme for these studies is that LoF-phenotype asso-
ciations were found both in established disease-trait
genes, such as PCSK9 (with plasma LDL levels) and
APOC3 (with plasma triglycerides), as well as in novel
genes associated with unexpected clinical traits [15, 19].
Thus, systematically discovering LoF-harboring genes
associated with clinical traits appears to be an effective
approach towards precision medicine [citation: https://
academic.oup.com/hmg/article/27/R1/R56/4969371] by
identifying novel disease candidate genes that may prove
useful as drug targets.
In the current study, we identified LoF variants with
possible implications for cardiovascular disease (CVD)
using Mount Sinai BioMe Biobank, established in 2007
in New York City, an ongoing, broadly-consented Elec-
tronic Medical Record (EMR)-linked data repository that
enrolls patients non-selectively from the Mount Sinai
Medical Center. So far, over 34,000 ancestrally diverse
participants have been enrolled, of which a subset of 10,
511 with genotype data were used here. Subjects have
been extensively characterized with longitudinal clinical
information in EMRs, including disease diagnoses, la-
boratory test results, and medication history [20, 21].
We have demonstrated successful utility of these data
for disease subtyping [22], automated phenotyping [cit-
ation: https://www.worldscientific.com/doi/abs/10.1142/
9789813235533_0014], comorbidity analyses [23, 24],
health assessment via real-time visualization [25], and
drug repurposing [26]. To validate CVD-trait gene asso-
ciations detected in BioMe, we used RNA sequencing
(RNAseq) data from blood and six vascular and meta-
bolic tissues in 600 well-characterized coronary artery
disease (CAD) patients of the Stockholm-Tartu Athero-
sclerosis Reverse Network Engineering Task (STARNET)
study [27]. A schematic flow of how we identified LoFs
in the BioMe Biobank, further evaluated corresponding
LoF-genes in STARNET and then undertook in vitro and
in vivo functional validation is shown in Fig. 1.
Methods
BioMe research cohort
In the current study, we utilized a genotyped biobank
cohort within the Icahn School of Medicine at Mount
Sinai. The Charles Bronfman Institute for Personalized
Medicine (http://icahn.mssm.edu/research/institutes/
ipm) BioMe Biobank is a repository that consists of over
34,000 enrolled participants. Currently, 11,212 individ-
uals are genotyped using the Illumina Human Omni Ex-
press Exome Bead-8 BeadChip v1.1, which has 866,864
markers per sample. BioMe actively recruits individuals
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Fig. 1 (See legend on next page.)
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from upper Manhattan facilitating strong representation
of ethnic minorities often underrepresented in other
studies. Out of the genotyped individuals, there were
6857 (61.2%) women and 4350 (38.8%) men, with three
individuals removed due to unknown sex. The self-
reported ancestry breakdown is as follows: 2090 (18.6%)
European, 3763 African American (33.6%), 5194 His-
panic/Latino (46.3%), and 134 Other (0.01%). Due to low
representation, we merged the remaining ancestry
groups into the “Other” category. The mean age for the
BioMe participants was 55.8 ± 15.8 years.
Genotype imputation, quality control, and filtration
For the genotype data, all individuals had call rates
above 99% and all SNPs had call rates > 95%, at least
one minor allele, and Hardy–Weinberg equilibrium
p-value >5e-05. We performed phasing on the genotype
data using SHAPEIT v2 (r644) [28] and imputation using
IMPUTE2 v2.3 [29] (chunk size of 5Mb). For the imput-
ation reference panel, we used the 1000 Genomes [30]
Phase 1 version 3 variant set (August, 2012; https://
mathgen.stats.ox.ac.uk/impute/data_download_1000G_
phase1_integrated.html). We then performed several
quality control steps on the over 37 million imputed
SNP data: 1. We removed any sites with < 0.3 gen INFO
score (from IMPUTE2); 2. We discarded any variants
with < 90% site completeness; 3. We removed individual
allele call below 95% genotype probability.
We used PLINK [31] to identify related individuals
(relatives) in the cohort that could bias the results of
subsequent analyses. We identified 612 pairs of individ-
uals (1224 total) that had PI-HAT scores > 0.2, which in-
dicates direct relatedness. Accordingly, we randomly
selected an individual from each pair to remove from
our cohort. After all of the QC steps detailed, the cohort
contained 10,511 individuals.
Variant annotation procedure
As different annotators have their strengths and weak-
nesses, we decided to utilize multiple annotators to iden-
tify predicted LoF mutations. All annotators were run
using the hg19 build. Variant Annotation Tool (VAT) is
an annotator that was used in the seminal paper by
MacArthur et al. [12] to identify LoF mutations. We ob-
tained the VAT annotated file from 1000 genomes [30]
ftp server (ftp://ftp-trace.ncbi.nih.gov/1000genomes/ftp/
phase1/analysis_results/functional_annotation/anno-
tated_vcfs/), specifically phase 1, version 3, where full
documentation can be found. We limited the variants to
those that putatively cause LoF by restricting “effect_
type” to “frameshift_indel”, “stop_gained”, or “splice_
site”. We also restricted these variants to those with pre-
dicted “full” effect. These filtering steps resulted in 4757
VAT-predicted LoF mutations for our dataset.
ANNOVAR is another variant annotator tool utilized
in a related follow-up study by Li et al. [15]. Like with
the previous annotator, we ran our dataset mimicking
the same parameters used in their study to identify LoFs
using ANNOVAR (v. 2015Apr14). Specifically, we fil-
tered the resulting “Gene-based Annotation” results for
variants causing “frameshift substitution”, “stopgain”, or
“exonic;splicing”. We obtained 10,582 predicted LoFs
from these filtering steps.
SnpEff [32] is a popular annotation tool that has been
used in many studies. To identify LoF mutations, we ran
our dataset using this tool (SnpEff v. 3.6) and filtered for
SNPs with “HIGH” Effect_Impact, “protein-coding” Tran-
script_BioType, and the following Effect types: “STOP_
GAINED”, “SPLICE_SITE_ACCEPTOR”, “SPLICE_SITE_
DONOR”, or “FRAME_SHIFT”. We identified 6387 puta-
tive LoFs from our dataset using these criteria.
Consensus LoF variant classification
We only included into our analyses consensus muta-
tions, or mutations in which at least two of three an-
notators identify as LoF. Additional file 1: Figure S1
demonstrates the relative distribution of LoF annota-
tion between the three annotators. It is important to
note that the overall numbers of variants called per
annotator might differ from the effect calls per anno-
tator as a particular variant can have more than one
effect call. In total, we identified 6421 putative con-
sensus LoF variants. We next performed extensive,
further QC curation to ensure high confidence and
(See figure on previous page.)
Fig. 1 Overall workflow of the study. We first identified high-confidence LoFs in genotyping and the imputed data from the BioMe Biobank (a).
Then for each gene with a LoF, we partitioned the BioMe individuals into LoF carriers and non-carriers (b) for comparison of 10 CVD-related traits
obtained from the Mount Sinai Hospital Electronic Medical Records (MSH-EMR) (c). Next, we performed trait-specific quality-control (QC) by
considering that the CVD-traits are affected by certain ongoing medications (d), followed by statistical analyses to robustly identify LoF-genes that
were significantly associated with at least one of these CVD traits (e). In the next step (f), we assessed LoF-harboring genes associated with any of
the CVD traits by exploring associations between RNA expression levels of these genes and corresponding CVD traits across seven tissues in
STARNET [27]. We then selected genes with concordant CVD trait-associations in both BioMe and STARNET (i.e., when LoFs in a gene are
associated with low values of a CVD trait, low expression of the same gene is also associated with low values of the trait) (g). For LoF genes
associated with lower plasma cholesterol or triglyceride levels in BioMe Biobank and STARNET liver data, we carried out functional in vitro
evaluation using HepG2 cells (H). Last, a knowledge-driven filtration approach was used for leveraging information in Gene Ontology (GO) to
select potential therapeutic targets for validation in mice (i)
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quality LoF annotation. From the imputation-specific
QC, we only kept variants that had > 0.3 gen INFO
scores (IMPUTE2; 1666 failed) and > 90% site com-
pleteness using 95% as call threshold (301 failed).
Furthermore, we excluded low confidence alleles with
quality scores < 95%. Additionally, we only included
variants that: 1) had consensus LoF annotation on at
least one overlapping transcript (i.e., only include
variant if two or more annotators classified the same
associated transcript as LoF; 28 failed); 2) were not in
the final exon of the predicted LoF transcript (1498
failed); 3) had < 2% alternate allele frequency (362
failed). Taken together, these filtering steps resulted in
the removal of 2029 unique variants (as a single vari-
ant could fail overlapping filtering steps), leaving 3392
unique remaining variants from the original list of
6421. Lastly, we filtered variants in which there were
no carriers in our cohort, which produced 2818 high
Fig. 2 The predicted LoF variants in the BioMe Biobank cohort. a Allele frequency of all LoF variants in BioMe Biobank population. b Distribution
of the number of LoF variants per gene. c Carrier frequency of LoF genes. d Number of LoF genes carried per person
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confidence predicted LoF variants for use in our
study (see Additional file 1: Figure S2A for variant fil-
tering procedure overview).
As a matter of practicality, we collapsed mutations to
the gene level, as the predicted outcome of each inde-
pendent LoF mutation within a single gene is theoretic-
ally identical. The relative distributions of mutations per
gene can be seen in Fig. 2b. On average, we found
1.32 ± 0.73 (STD) LoF mutations per gene, with a max-
imum of 9 mutations in the gene PZP, which has 65,552
base pairs. The frequency of these mutations in the
population can be seen in Fig. 2c. Specifically, the 2818
variants were collapsed into a useable list of 2143 genes.
The distribution of LoF gene frequency in this popula-
tion can be seen in Fig. 2d. We present all variants used
in this study along with their frequency in our cohort
and their respective effect call for each annotator in
Additional file 2: Table S1.
Trait data collection and processing
The BioMe Biobank cohort used in this study is con-
nected to the MSH’s EMR via de-identified codes man-
aged by the Mount Sinai Data Warehouse. These
records contain information on trait measurements and
medication prescriptions, which we collected for all of
the individuals in the cohort. We selected 10 CVD-
related traits for analysis, specifically: glucose levels,
hemoglobin A1c, total cholesterol, LDL cholesterol,
HDL cholesterol, triglycerides, high sensitivity C reactive
protein, diastolic blood pressure, systolic blood pressure,
and white blood cell count. We obtained trait measure-
ments through querying the EMR, which consisted of
individual, value, date, and unit of measurement. This
cohort, however, was not specifically screened for enroll-
ment criteria. As such, there are many factors that could
have extreme effects on the trait values that are irre-
spective of genetics. Of crucial concern are changes in
trait levels due to diseases and/or medication use. While
several algorithms exist to control the effect of medica-
tions in trait analytics, there is no established, universal
methodology. Accordingly we devised a thorough and
individualized procedure to control for confounding fac-
tors, including disease and medication effects, in the
current study, which we describe in detail in the Add-
itional file 1: Supplementary Materials.
In brief, we performed several QC steps on the trait
measurement data to ensure the highest achievable val-
idity (Additional file 1: Figure S2B). We filtered out all
incorrectly labeled, outlier, and medication/disease-af-
fected measurements, and then combined any remaining
measurements into a single median value per person.
For each of the 10 traits, we present the exclusion QC
process (i.e. number of individuals and total number of
measurements before and after filtering) in Additional
file 2: Tables S3-S5; specifically due to medication use
(Additional file 2: Table S3), outliers (Additional file 2:
Table S4), and combined (Additional file 2: Table S5).
Association analysis between LoF genes and traits
We performed linear regression analysis to test
whether having a LoF mutation significantly affects
trait measurements. Our analytical goal was to assess
if genes harboring LoF genetic variants were signifi-
cantly associated with CVD traits. Therefore, we
chose to perform the analysis at gene level rather
than at the level of individual variants. CVD trait
values and ages used in the analyses were median
values that passed QC steps explained previously.
We observed the regression residuals were not
approximately normally distributed and thus would
not satisfy assumptions of linear regression. Accord-
ingly, we first performed the Box-Cox transformation
(Eq. 1) procedure to identify the optimal transform-
ation parameter per trait that produces a normal dis-
tribution of residuals by sequencing through λ values
from the range [− 2, 2] in increments of 0.5. The
natural logarithm was used for the case of λ = 0. For
each trait, we selected the λ value corresponding to
the highest regression model (Eq. 2 without the gene
variable) log-likelihood as the optimal transformation
parameter. All regressions were generalized linear
models fit to the data using the method of iteratively
reweighted least squares. The effects of transform-
ation can be found in Additional file 1: Figure S8.
y λð Þi
y λð Þi −1
λ
ifλ≠0





With the lambda parameter calculated, we then per-
formed the following formula to assess for genotype-
trait significance:
Pðtraitλjβ0 þ βl  geneþ βg  sexþ βa  age
þβpc1  PC1… þ …βpc5  PC5Þ
ð2Þ
where trait is continuous value, λ is the transformation
parameter factor derived through Box-Cox transform-
ation (Eq. 1), gene is binary piecewise Yes/No indicating
presence of LoF mutation, sex is binary piecewise Fe-
male/Male, age is continuous constant per year, principal
components are continuous.
To obtain an estimate of effect size, for associations
that were found to be significant in (Eq. 2), we per-
formed a similar statistical analysis albeit without re-
sponse transformation and used both βl and t-statistic
(βl / β standard error).
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RNA-expression data source: STARNET
The details of the STARNET study have been previously
published [27], however in brief: patients diagnosed with
CAD undergoing open-heart surgery had up to 7 tissues
collected, including aortic root (AOR), whole blood, liver
(LIV), mammary artery (MAM), subcutaneous fat (SF),
skeletal muscle (SKLM), and visceral fat (VAF). RNA
was derived from each tissue and sequenced at read
lengths of 50 or 100 base pairs from a single-end. Reads
were aligned to human genome hg19 using the STAR
aligner [33] version 2.3.0e and GENCODE v19 [34] an-
notations. Reads aligned to genes were summarized
using HTSeq [35]. For each tissue, genes with less than
one count per million (CPM) in more than 90% of sam-
ples were filtered. Genes passing this criteria were nor-
malized using voom [36] using the ‘TMM’ method,
generating log (CPM) values and precision weights. A
linear model was then used to adjust for batch effects
using sequencing flow cell identifier. An lmFit object
was generated with the general formula log (CPM) ~
FlowCellID. The residuals of this linear model were used
as batch-normalized gene expression values in subse-
quent analysis.
Association analysis between gene expression and traits
We compared the RNA expression levels of the identi-
fied LoF genes in all STARNET tissues to the same 10
CVD traits. Linear modeling was performed to assess
the correlation between gene expression and clinical
trait, after adjustment for basic clinical covariates. The
model used was: Trait ~ Gene + Age + Gender + BMI.
Integration of BioMe data and STARNET data
We assumed that LoF variants in BioMe and low gene
expression level in STARNET have the same biological
and consequently physiological effect. Therefore we de-
fined concordant associations in BioMe and STARNET
as follows: when LoFs in a gene are associated with low
values of a CVD trait in BioMe, low expression of the
same gene is also associated with low values of the trait
in STARNET; conversely when LoFs in a gene are asso-
ciated with high values of a CVD trait in BioMe, low ex-
pression of the same gene is also associated with high
values of the trait in STARNET. Furthermore, we con-
sidered the associations in BioMe and STARNET con-
cordant regardless what tissues in the STARNET data
where significant associations between gene expression
and CVD-traits were observed. To illustrate the defin-
ition of concordant associations in BioMe and STAR-
NET, in Table 2, LoF in gene ACSM3 is associated with
low LDL cholesterol level in BioMe, and low gene ex-
pression of ACSM3 is also associated with low LDL
cholesterol level in skeletal muscle (SKLM) in STAR-
NET; conversely, LoF in gene ACOT11 is associated
with high glucose level in BioMe, and low gene expres-
sion of ACOT11 is also associated with high glucose
level in skeletal muscle (SKLM) in STARNET.
Mouse DGAT2 validation procedure
In the current study, C57BL/6 wild type male mice
(3 months old, fed chow diet) were obtained from the
Jackson Laboratory. The animals were maintained in a
pathogen-free and temperature-controlled room on a 12
h light/dark cycle and supplied with food and water ad
libitum. Compounds were administered as previously
described [37, 38] with modifications, specifically, mice
were orally dosed with vehicle (control) or inhibitors 20
mg/kg/day. Body weight and fasting glucose were mea-
sured 3 days after compound treatment.
siRNA candidate targets validation study
Cells from the human hepatocellular carcinoma cell line
HepG2 were plated in six-well culture dishes (Corning)
containing 10% fetal bovine serum (FBS)-RPMI-1640
medium supplemented with penicillin (100 U/mL) and
streptomycin (100 μg/mL). For each gene, cells were
transfected with siRNAs (Ambion, Life Technologies,
Additional file 2: Table S9), using Lipofectamine Rnai-
Max according to the manufacturer’s instructions (Invi-
trogen). Two days after transfection, siRNA-targeted
cells and mock-treated controls (scramble siRNA) were
incubated with oleic acid (0.75 mM, Sigma Aldrich,) for
24 h in 1% FBS medium. Thereafter, the cells were ex-
amined for effects on levels of PCSK9 and LDLR, and
on measurements of cholesterol (total cholesterol, TC;
and cholesteryl esters, CE) and triglycerides (TG).
Total RNA was isolated from HepG2 cells with the
RNeasy Mini-kit (Qiagen) and concentrations deter-
mined by NanoDrop (Thermo Scientific). The efficiency
of target gene silencing was determined by TaqMan ana-
lyses (Additional file 2: Table S9). In brief, cDNA was
synthesized from 0.5 μg of total RNA (High-Capacity
RNA-to-cDNA Kit, Thermo Scientific) and amplified by
real-time PCR with 1xTaqMan universal PCR master
mix (Applied Biosystems) using primers and probes
from Applied Biosystems (Additional file 2: Table S9);
data were normalized to mock control using the com-
parative Ct method.
Cholesterol and triglyceride measurement procedure
Cholesterol accumulation in cell lysates of siRNA-targeted
HepG2 cells was measured using the Total Cholesterol
and Cholesteryl Ester Colorimetric/Fluorometric Assay kit
(BioVision). Lipid levels were normalized by protein con-
centrations obtained from the same samples using the
BCA method (Thermo Scientific). Triglycerides from
siRNA targeted HepG2 cells were determined by an
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enzymatic assay using the Triglyceride Quantification
Colorimetric/Fluorometric Kit (BioVision).
ELISA assay to measure PCSK9 and LDLR plasma levels
PCSK9 levels were measured using the Human PCSK9
ELISA kit (Cell Biolabs, INC.), according to manufac-
turer instructions. LDLR levels in cell lysates were mea-
sured using the Human LDLR ELISA kit (R&D
Systems), according to manufacturer instructions. Ab-
sorbance for both methods was quantitated on Promega
Glomax reader at 450 nm.
Experimental statistical analyses
All experiments were performed in triplicate from 3
independent experiments; data are shown as mean ±
SEM. Statistical differences were assessed with un-
paired 2-tailed Student t-tests. Values of P < 0.05 were
considered statistically significant. Computations were
performed with GraphPad Prism 6 software (La Jolla,
CA 92037 USA).
Results
LoF-harboring genes associated with CVD traits in BioMe
Genotyping and imputed data from 11,212 individuals of
the BioMe Biobank were used to identify a total of 2818
LoFs in 2143 different genes (Methods; Additional file 1:
Figure S1; Additional file 1: Figure S2A). Among the
2818 LoFs, 2117 (75%) were genotyped in the BioMe
data, and the rest of the LoFs have been previously iden-
tified through direct sequencing in databases such as
1000 Genomes [30] and ExAC [39] (Additional file 2:
Table S1). Most of the identified LoFs (95%) were rare
(allele frequency < 0.5%, Fig. 2a) and most genes (2009/
2143 [94%]) had ≤2 LoFs (Fig. 2b). Approximately 60%
of those genes with LoFs had 10 or fewer carriers
(Fig. 2c). Among individuals carrying at least one LoF,
LoFs were typically found in less than 10 genes (mean
5.7, median 5.0; Fig. 2d).
Next, we selected 10 CVD-traits from the MSH-EMR
associated with the BioMe individuals (Fig. 1), namely:
glucose levels, hemoglobin A1c, total cholesterol, LDL
cholesterol, HDL cholesterol, triglycerides, high sensitiv-
ity C reactive protein, diastolic blood pressure, systolic
blood pressure, and white blood cell count. Before ana-
lyzing these traits in relation to LoFs, we removed trait
data that was associated with ongoing medication use
that potentially affected the trait (Supplementary
Methods; Supplementary Results; Additional file 1: Fig-
ure S2B; Additional file 1: Figure S3-S6; Additional file
2: Table S2-S5). We required there to be at least three
carriers of LoFs for a given gene with CVD-trait mea-
surements in order to be analyzed, resulting in 1371 of
the original 2143 genes examined for their association
with CVD traits (see Methods). A total of 644 significant
LoF-CVD trait associations involving 433 genes were
identified (linear regression, p < 0.1) (Fig. 1; Additional
file 2: Table S6). 79% of the LoFs associated with a CVD
trait were genotyped. The LoF genes were both associ-
ated with higher and lower levels of the CVD traits
(Additional file 1: Figure S4). The statistically most sig-
nificant LoF-CVD trait association was reassuringly
found in PCSK9 associated with lower plasma LDL chol-
esterol (p = 1.1E-09, β = − 43 mg/dL) as well as plasma
cholesterol (p = 4.3E-07, β = − 44mg/dL; Additional file
2: Table S6). We also identified a LoF in APOC3 that
was associated with reduced levels of plasma triglycer-
ides (p = 5.6E-03, β = − 60mg/dL) as expected.
Integrating RNA expression evidence from STARNET to
the putative associations
Limitations of the BioMe Biobank analysis of LoFs re-
volve mainly around sample size, availability of trait
measurements, trait filtration, and the low frequency of
most LoFs (see also Discussion). As such, many of the
LoF-CVD trait associations may risk being inflated due
to a skewed distribution of CVD trait levels in a few LoF
carriers. At the same time, sample size issues could mask
true associations trending towards significance (hence
we used a less stringent cutoff p < 0.1). To address some
of these limitations and to seek functional evidence as to
what organ the LoF may impact for a given CVD trait,
we sought associations between the expression levels of
LoF-harboring genes and corresponding CVD traits in
RNAseq data from the STARNET study [27] (Fig. 1; see
Methods). Of the 644 LoF-CVD trait associations found
in BioMe, 241 also had at least one significant (p < 0.05)
gene expression-CVD trait association in STARNET in
at least one of the seven tissues, corresponding to 194
unique genes (Fig. 1). Out of these, 115 unique genes,
134 gene-trait associations and 165 combinations of
gene-trait-tissue associations were concordant (Fig. 1;
Additional file 2: Table S7), i.e. LoFs associated with
lower levels of a CVD trait in BioMe also showed a posi-
tive correlation with expression levels in STARNET and
vice versa. In the 115 genes with concordant associa-
tions, 82% of the LoFs were genotyped. The discordant
significant results between the two data sources, while
not considered for follow-up evaluation, could still re-
flect true biological associations that could not be reli-
ably discerned due to study limitations.
Validation of hepatic gene targets predicted to lower
plasma cholesterol and triglyceride levels in an in vitro
model
We selected 10 genes (Table 1) associated with either
lower plasma cholesterol or triglyceride levels in both
BioMe (β < 0, p < 0.1) and STARNET liver tissue (β > 0,
p < 0.05) for further experimental validation by
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performing gene silencing using the HepG2 in vitro cel-
lular model of hepatocytes. A hepatocyte model was se-
lected since the liver is the primary organ responsible
for regulating systemic cholesterol and triglyceride levels
(see below). Five genes, CYP2C19, PCK2, RNMTL1
(MRM3), SCRN2, UGT1A4, associated with lower levels
of plasma cholesterol (Fig. 3a) were selected due to their
potential role in hepatic cholesterol metabolism for in
vitro validation. PCK2 was included at our significance
threshold (p = 0.10) and UGT1A4 and RNMTL1 were
included using lower variant imputation genotype prob-
ability scores, making in silico results from these in this
analysis more speculative. Validation was performed by
measuring intracellular levels of LDLR and in media,
PCSK9 and APOB100 after individual silencing by
siRNA in HepG2 cells (Fig. 3b). While we observed ro-
bust expression levels of PCK2, RNMTL1, and SCRN2 in
HepG2 cells, CYP2C19 and UGT1A4 were not expressed
at detectable levels and were therefore excluded from
the validation. For these experiments, PCK2, RNMTL1
and SCRN2 achieved > 90% inhibition of gene expres-
sion by siRNA (Additional file 2: Table S9). Individual
silencing of RNMTL1 and SCRN2 both significantly
reduced levels of media APOB100 and PCSK9 and
concurrently increased cellular LDLR levels (Fig. 3c).
Silencing of PCK2 also reduced media levels of
APOB100 and PCSK9 but had no significant effect on
LDLR levels (Fig. 3c).
Gene silencing in HepG2 cells was also used to con-
firm the role of APOC3, and to assess the function of
three novel candidate genes (ABHD14B, NMRAL1, and
SLC39A5) found to be associated with lower levels of
plasma triglycerides in BioMe and STARNET liver data.
CES3 was not selected for further in vitro validation be-
cause of its well-documented effect in lowering plasma
triglycerides and cholesterol levels in liver-specific KO
mice [40] and in reducing the secretion of ApoB100 and
triglyceride by its pharmacological inhibition in human
hepatocytes [41]. As the liver has negligible or no role in
regulating plasma triglyceride uptake, the roles of the
three new hepatic genes ABHD14B, NMRAL1, and
SLC39A5 (if any) most likely are through facilitating
hepatic secretion of very-low density lipoproteins
(VLDL, Fig. 3a). APOC3 is best known for increasing
plasma triglyceride levels by interfering with lipoprotein
lipase-mediated hydrolysis of plasma triglyceride-rich
VLDL particles on the endothelial surface of peripheral
tissues (e.g., in fat). However, recent evidence shows that
hepatic APOC3 also facilitates the secretion of VLDL
from the liver [42]. Silencing of APOC3 and SLC39A5 in
HepG2 cells reduced media levels of APOB100 and tri-
glycerides and at the same time increased intracellular
levels of triglycerides, presumably due to secondary
accumulation following reduced secretion of VLDL
(Fig. 3d). Silencing of NMRAL1 and ABHD14B, respect-
ively, reduced and markedly increased media levels of
APOB100 but had no apparent effect on levels of media
or cellular triglycerides.
A knowledge-driven approach to identify targets for in
vivo validation
We also applied a knowledge-driven approach to valid-
ate potential therapeutic targets in parallel with the
data-driven approach (Fig. 1). We filtered the complete
list of 115 genes with concordant associations in BioMe
(LoF-CVD trait) and STARNET (expression-CVD trait,
in any tissue) using GO annotations. A total of 90 genes
(78.3%) had at least one GO-associated biological
process term. Nine of these 90 genes corresponding to
11 gene-trait associations had at least one GO term re-
lated to the CVD traits of interest (e.g., biological pro-
cesses relating to blood pressure, glucose, cholesterol or
Table 1 Selection of novel genes involved in regulating cholesterol or triglyceride levels for in vitro functional studies










CYP2C19 Cytochrome P450 Family 2 Subfamily C Member 19 TC 0.089 −32 0.033 0.10 LIV
PCK2 Phosphoenolpyruvate Carboxykinase 2,
Mitochondrial
TC 0.10 −23 0.00053 0.55 LIV
RNMTL1 RNA methyltransferase-like protein 1 TC 0.054 −36 0.016 0.60 LIV
SCRN2 Secernin 2 TC 0.089 −26 0.0026 0.39 LIV
UGT1A4 UDP Glucuronosyltransferase Family 1A4 TC 0.069 −13 2.1E-05 0.70 LIV
ABHD14B Abhydrolase Domain Containing 14B TG 0.027 −11 0.026 0.47 LIV
APOC3 Apolipoprotein C3 TG 0.0056 −56 0.0065 0.38 LIV
CES3 Carboxylesterase 3 TG 0.061 −40 0.00011 0.42 LIV
NMRAL1 NmrA-Like Family Domain Containing 1 TG 0.080 −28 0.045 0.28 LIV
SLC39A5 Solute Carrier Family 39 Member 5 TG 0.092 −70 0.0036 0.43 LIV
Negative β in BioMe and positive β in STARNET indicate LoF and low gene expression are associated with decreased trait measurements
LIV liver, TC total cholesterol, TG triglycerides
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triglycerides) (Table 2; Additional file 2: Table S8 for GO
annotation).
Of these, we selected DGAT2 for follow-up validation
for several reasons. First, the DGAT2 expression-CVD
trait association for glucose levels was identified in liver
(Table 2), a tissue type with more biological relevance to
the trait. Second, pharmacological inhibitors of DGAT2
are available (Futatsugi et al. 2015) for further experi-
mental validation. Most importantly, a homolog of
DGAT2, DGAT1, has been extensively pursued as a
therapeutic target for obesity and diabetes yet with
limited clinical success (see below), and we wanted to
explore if DGAT2 would be a more viable target.
DGAT2 exhibited significant associations with plasma
cholesterol and glucose levels in both BioMe and
STARNET (Table 2). In the BioMe Biobank, we iden-
tified a stop-gain LoF based on genotyping data (stop
codon Y285*, 0.001% allele frequency) found in 12
heterozygous individuals located in the middle of the
enzymatic domain of DGAT2 (Additional file 1: Figure
S7A) that likely triggers non-sense mediated decay
resulting in no protein synthesis (Additional file 1:
Figure S7B and S7C). Individuals with this LoF had
significantly (p < 0.1) lower plasma glucose (Fig. 4a)
and cholesterol (Fig. 4b) levels and statistically
non-significant (p > 0.1) lower plasma triglycerides
Fig. 3 In vitro validation of candidate genes for lowering plasma cholesterol and triglycerides. a Schematic illustration of lipoprotein metabolism
in vivo, and b An in vitro HepG2 cell model to validate three hepatic plasma cholesterol and three hepatic triglyceride candidate genes. I)
Cholesterol- and triglyceride-containing very low density lipoprotein (VLDL) particles are synthesized in, and secreted from, the liver to circulation
elevating plasma levels of cholesterol and triglycerides. II) The VLDL particles then travel in blood to microcirculation in peripheral tissues, such as
the skeletal muscle and adipose tissue, where lipoprotein lipase (LPL) anchored to the endothelium mediates hydrolysis of VLDL-triglycerides
forming free fatty acids that are taken up by the local tissue. This extra-hepatic process lowers plasma triglyceride levels. III) The LPL-mediated
hydrolysis of VLDL particles results in the formation of smaller cholesterol-rich low-density lipoproteins (LDL) particles. Some LDL particles are
taken up by LDL receptors in extra-hepatic tissues, a process that lowers plasma levels of LDL and cholesterol. IV) The most important regulatory
process of plasma LDL and cholesterol levels is, however, the uptake of LDL by hepatic LDL receptors. V) Last, uptake of LDL by the LDL receptor
in the liver is inhibited by hepatic synthesis of PCSK9 that binds to the LDL receptors and permits their recirculation away from the hepatocyte
cell surface (and LDL receptor degradation) effectively lowering the uptake of LDL particles. Thus, high levels of hepatic PCKS9 lead to reduced
LDL uptake and higher plasma cholesterol levels. The HepG2 in vitro model of the liver was chosen as it is the most important organ to control
plasma triglyceride and cholesterol levels (a) and since all lipid-associated candidate genes were identified in STARNET liver RNA-seq data.
However as illustrated in panels a and b, an in vitro model of the liver in the form of HepG2 cells cannot fully model lipid metabolism and the
extrahepatic tissue contribution in vivo. c For the plasma cholesterol-lowering candidate genes (RNMTL1, SCRN2 and PCK2), Apolipoprotein B-100
(APOB-100), Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) protein levels were measured in the cell media whereas LDL-receptor (LDLR)
was measured in cell lysates. d For the plasma triglyceride-lowering candidate genes (APOC3, SLC39A5, NMRAL1, ABHD14B), Apolipoprotein B-100
(APOB-100), triglycerides (TG) were measured in cell media and lysates. In all experiments, the silencing efficiency of each gene resulted in more
than 90% decrease in gene expression measured after 72 h incubation, including 24 h treatment with oleic acid performed before cell harvesting.
Values are means ± SEM. Results are based on 3 biological replicates. p < 0.0332 (*), p < 0.0021 (**), p < 0.0002 (***). IDL, intermediate-density
lipoprotein. Computational analysis results of the genes tested in (c) and (d) are shown in Additional file 1: Figure S9
Glicksberg et al. BMC Medical Genomics 2019, 12(Suppl 6):108 Page 10 of 16
(Fig. 4c). Corresponding positive and significant
(p < 0.05) associations with plasma levels of glucose,
cholesterol and triglycerides were also observed for
hepatic DGAT2 expression in STARNET (Fig. 4d-f ).
DGAT catalyzes the final step in triglyceride synthesis
[43] and there are two known DGAT enzymes, DGAT1
and DGAT2. DGAT1 has been extensively investigated
as a therapeutic target for obesity and obesity-related
metabolic disorders such as insulin resistance. Across
several preclinical studies [37, 44, 45], DGAT1 inhibitors
were shown to reduce body weight and improve insulin
sensitivity. In contrast, DGAT2 inhibition has not been
extensively investigated. Among the limited studies per-
formed so far, antisense oligonucleotides against DGAT2
lowered hepatic lipid levels in mice [46–48], however,
pharmacological inhibition of DGAT2 with selective
small molecule inhibitors has not been reported.
To evaluate the effect of specific inhibition of DGAT2
and to compare this with inhibition of DGAT1, we
treated C57BL/6 mice with a highly selective DGAT1
small molecule inhibitor PF-04620110 (PF3) [49] or a
highly selective DGAT2 inhibitor PF-06424439 (PF9)
[38]. Treatment with the DGAT1 inhibitor was associ-
ated with significantly decreased body weight (Fig. 4g)
and fasting glucose levels (Fig. 4h), consistent with
previous reports [37, 44]. Similar effects were observed
in mice treated with the DGAT2 inhibitor (Fig. 4g and
h). However, whereas weight loss following DGAT2 in-
hibition was borderline significant (Fig. 4g), the lowering
of fasting plasma glucose levels was more pronounced
than in mice treated with the DGAT1 inhibitor (Fig. 4h).
Discussion
In drug discovery and development, half of all therapeu-
tics fail in phase 2 clinical trials due to lack of efficacy
[50]. This is immensely expensive and pharmaceutical
companies are urgently looking for new strategies to bet-
ter select targets at an earlier stage. In this regard, the
power and accuracy of human genetics for target selec-
tion is increasingly being recognized [11]. In the current
study, we identified and cataloged 2818 LoFs in 2143
genes from genotyping and the imputed data in the
Mount Sinai BioMe Biobank [51]. LoFs in 433 of these
genes were found to be associated with at least one of
10 major CVD traits in clinical data of the MHS-EMRs
after careful annotation. 115 genes were further con-
firmed as being concordantly associated with the same
trait in the world’s largest human RNAseq datasets from
blood, vascular, and metabolic tissues in STARNET [27].
Although the genetic data in BioMe is based on genotyping
Table 2 Significant gene-trait associations (BioMe p < 0.1, STARNET p < 0.05) of genes known to be involved in lipid and glucose
metabolism based on GO annotation










ACOT11 Acyl-CoA Thioesterase 11 GO:0006631 (fatty acid
metabolic process)
Glucose 0.059 40 0.040 −0.28 SKLM
ACSM3 Acyl-CoA Synthetase Medium-





0.060 −4.3 0.032 0.10 SKLM
ADCY4 Adenylate Cyclase 4 GO:007137 (cellular response to
glucagon stimulus)
Glucose 0.0095 39 0.025 −0.40 MAM




0.034 1.4 0.034 −0.14 SF
AGMO Alkylglycerol Monooxygenase GO:0019432 (triglyceride
biosynthetic process)
Glucose 0.094 −16 0.021 0.33 AOR
APOC3 Apolipoprotein C3 GO:0006641 (triglyceride
metabolic process)
Triglycerides 0.0056 −56 0.0065 0.38 LIV
DGAT2 Diacylglycerol Acyltransferase 2 GO:0019432 (triglyceride
biosynthetic process)
Glucose 0.049 −19 0.024 0.56 LIV
DGAT2 Diacylglycerol Acyltransferase 2 GO:0019432 (triglyceride
biosynthetic process)
Cholesterol 0.078 −24 0.036 0.089 MAM




0.039 11 0.0021 −0.21 MAM




Glucose 0.042 −15 4.6E-05 0.65 LIV





0.030 1.9 0.027 −2.6 MAM
AOR aorta, MAM mammary artery, LIV liver, SF subcutaneous fat, SKLM skeletal muscle. β values represent effect size. Positive β in BioMe and negative β in
STARNET indicate LoF and low gene expression are associated with increased trait measurements. Negative β in BioMe and positive β in STARNET indicate LoF
and low gene expression are associated with decreased trait measurements
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and imputation, the majority (75%) of the analyzed 2818
LoFs and 82% of the LoFs in the 115 genes with concordant
associations were genotyped, enhancing our confidence in
the results. Using complementary data- and knowledge-
driven approaches, we then successfully validated five novel
liver genes for lowering of plasma cholesterol and triglycer-
ides in HepG2 cells. In addition, we revealed that DGAT2
inhibitors have marked effects on plasma glucose in vivo.
Fig. 4 In silico analysis of DGAT2 and in vivo effect of selective DGAT1 and DGAT2 inhibitors on bodyweight and glucose levels in male C57BL/6 mice. a
Significant association within the BioMe Biobank cohort between non-carriers (n = 5469) and carriers (n = 8) of LoF DGAT2 mutation on glucose level
(logistic regression, see Methods; p = 0.049, β=− 19, tβ =− 1.4). b Association between non-carriers (n = 4768) and carriers (n = 8) of LoF DGAT2 mutation
on cholesterol levels (logistic regression, see Methods; p = 0.078, β=− 24, tβ =− 1.8). c Association between non-carriers (n = 4721) and carriers (n = 8) of
LoF DGAT2 mutation on triglyceride levels (logistic regression, see Methods; p = 0.34, β=− 26, tβ =− 1.0). d Association from STARNET RNA-clinical trait
analysis comparing DGAT2 expression levels with glucose levels in liver tissue (p = 0.024, β= 0.56). e Association from STARNET RNA-clinical trait analysis
comparing DGAT2 expression levels with cholesterol levels in mammary artery (p = 0.036, β= 0.089). f Association from STARNET RNA-clinical trait analysis
comparing DGAT2 expression levels with triglyceride levels in liver tissue (p = 0.0030, β= 0.27). g Body weight loss (ΔBW) of chow-fed mice treated for 3
days with vehicle, DGAT1 inhibitor (PF3), and DGAT2 inhibitor (PF9). h Short fasting blood glucose of chow-fed mice treated for 3 days with vehicle, DGAT1
inhibitor (PF3), and DGAT2 inhibitor (PF9) (n = 5). p < 0.05 (*), p < 0.01 (**), versus vehicle (student t-test)
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This represents the first systematic study of a large,
hospital-based EMR-linked biobank to uncover and
catalog novel LoFs associated with CVD traits that
were then validated in global gene expression data.
As such, it serves to improve our understanding of
CVD biology and highlights novel putative CVD tar-
get genes that merit further investigation.
In comparison to the DiscovEHR study [19] where
176,000 LoFs were identified from 50,726 exomes, we
identified significantly fewer LoFs in the BioMe co-
hort. Besides a smaller sample size and different
makeup of ethnicity, the reason for the large discrep-
ancy in predicted number of LoFs between the studies
is that we used genotyping and the imputed data.
Nearly 60% of the LoFs detected in the DiscovEHR
cohort are singletons and 98.5% had an allele fre-
quency of < 0.1%. With respect to associations be-
tween LoFs and clinical traits, the DiscovEHR study
only focused on nine therapeutic targets with drugs
approved by the FDA or in clinical trials. In contrast,
we validated novel gene-trait associations in inde-
pendent gene expression data and carried out in vitro
and in vivo functional studies.
We identified six novel candidate CVD-related
genes using our pipeline. For these six genes we
found strong support for their roles in hepatic control
of plasma cholesterol (PCK2, RNMTL1 and SCRN2)
and triglyceride (ABHD14B, NMRAL1 and SLC39A5)
levels using gene silencing in HepG2 cells (Fig. 3).
None of the three plasma cholesterol-lowering candi-
date genes have previously been implicated in hepatic
cholesterol homeostasis (see Supplementary Discus-
sion). Given the pronounced and concordant effects
of silencing PCK2, RNMTL1, and SCRN2 in reducing
media levels of APOB100 and PCSK9 and increasing
the expression of LDLR in HepG2 cells (all but
PCK2) these genes should be further evaluated as
novel targets for lowering plasma cholesterol.
LoFs in three previously unassociated genes
(ABDH14B, NMRAL1 and SLC39A5), the documented
plasma triglyceride-related genes, APOC3 [52, 53] and
CES3 [40, 41] were found to be associated with lower
plasma triglyceride levels in BioMe and STARNET
liver data. Again using gene silencing in HepG2 cells
(Fig. 3), we not only found strong support for this
role of APOC3 but also equally for SLC39A5, with
concurrent and marked effects on levels of both
media and intracellular triglycerides and media
APOB100 (Fig. 3d). Silencing of ABDH14B and
NMRAL1 affected APOB100 secretion in opposite
ways but had no effect on either media or cellular
triglycerides. Taken together, our validation confirms
the role of APOC3, and strongly suggests that
SLC39A5 may be an interesting candidate gene for
lowering plasma triglyceride levels. For NMRAL1
and ABDHD14B, marked and opposite effect were
observed on media APOB100 whereas media and
cellular triglyceride levels were unaffected. Thus the
roles of these two genes require further scrutiny.
Our study also provided human genetic support for
DGAT2 as a therapeutic target, which has not previously
been reported. Although both DGAT1 and DGAT2
catalyze the same reaction in the last step of triglyceride
synthesis, often in the same cells, DGAT1 but not
DGAT2 has been pursued for more than a decade as a
therapeutic target for obesity and metabolic disorders
such as insulin resistance. This is primarily because
DGAT1 mouse knockout (KO) models are resistant to
diet-induced obesity, show decreased levels of tissue tri-
glycerides, and have increased sensitivity to insulin and
leptin [54, 55]. In contrast, DGAT2 KO mice die soon
after birth, apparently from profound reductions in en-
ergy metabolism substrates and impaired skin perme-
ability [56]. Although DGAT1 inhibitors consistently
demonstrate metabolic benefit in various animal models
[37, 44, 45], results from several clinical trials have been
disappointing [57]. Specifically, while most of the clinical
candidates exhibited the desired pharmacokinetic prop-
erties and target engagement, they failed to show effects
on GLP-1 levels and insulin sensitivity. Moreover, there
were gastrointestinal side effects such as nausea, diar-
rhea, and vomiting [57, 58]. Indeed, it was later discov-
ered that a rare LoF splice site mutation in DGAT1 in an
Ashkenazi Jewish family is linked to a congenital diar-
rheal disorder (CDD) [59]. Therefore, the lack of success
from inhibiting DGAT1 in humans, despite promising
results from animal models, may be explained by the dif-
fering phenotypes of DGAT1 deficiency in human and
mouse, again emphasizing the significance of target val-
idation using human genetics. Association of LoF muta-
tions or reduced expression in DGAT2 with reduced
plasma cholesterol and glucose levels in both BioMe and
STARNET cohorts in this study, coupled with the obser-
vation that a selective DGAT2 inhibitor had similar ef-
fects in mice as DGAT1 inhibitors (Fig. 4), suggests that
DGAT2 could be a more preferable therapeutic target in
humans than DGAT1.
We recognize there are several limitations to our
study. First, as noted above, biobank data is not gener-
ated based upon on a prospective design for specific dis-
eases or disease-relevant traits, hence clinical data
quality is a concern. Even though we developed a thor-
ough and individualized QC process for the 10 analyzed
traits, with manual curation by two cardiologists to com-
pile a list of medications and their related diseases that
may affect each trait, there could be other factors affect-
ing trait measurements that were not accounted for.
These may include unreported medication use or
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pathophysiologic conditions when the measurements
were taken. The sample size is another limitation with
biobank data. While we analyzed associations of LoF
genotypes with 10 CVD and metabolic traits, we also
attempted to perform similar association analysis on
risk for CVDs. However, due to small sample sizes
for each specific disease, the analysis did not yield in-
terpretable results and is thus omitted from this re-
port. Second, computational prediction of LoFs is still
an empiric, imperfect process. Without experimental
confirmation of each predicted LoF, there may be
false positive and false negative associations for each
gene. It is conceivable that some missense mutations
lead to diminished or complete loss of protein func-
tion, but they are not included in our analysis. This is
potentially problematic because LoFs are relatively
rare in the human genome, and any false positive or
false negative annotations may significantly impact
the sample size of the case group (i.e. LoF carriers),
causing identification of spurious LoF-trait associa-
tions. Third, genetic associations with diseases or dis-
ease related traits are often dependent upon racial
and ethnic background. While the BioMe Biobank is
racially diverse, the STARNET patients are predomin-
antly White Caucasians. Thus, lack of validation in
the STARNET cohort does not necessarily indicate
the LoF/CVD-trait associations identified the BioMe
Biobank cohort are false. However, genes with con-
cordant CVD-trait associations in both BioMe Bio-
bank and STARNET merit further scrutiny. In
addition, due to the relatively low frequency of many
of the variants characterized in this study coupled
with the sample size of the BioMe Biobank cohort,
we were underpowered to perform any form of strati-
fied analysis to assess the contribution of racial or
ethnic background to these associations. Lastly, we
elected to use uncorrected, lenient p-value thresholds for
both BioMe and STARNET data analyses (p < 0.1 and
p < 0.05, respectively) with the understanding that we
were less concerned with specific individual associations
but more with those that were orthogonally significant in
multiple datasets and validated experimentally.
Conclusion
In conclusion by leveraging the unique EMR-linked
BioMe Biobank, we were able to identify and catalog
433 LoF-harboring genes found to be associated with
at least one of 10 major CVD traits. Next and in con-
trast to recently published genotype-phenotype associ-
ation studies [15, 19, 60], we successfully validated
115 of these putative gene-CVD associations using
STARNET RNA-seq data from seven metabolic and
vascular tissues. As a result, experimental in vitro
validations of PCK2, RNMTL1 and SCRN2, and
ABHD14B, NMRAL1 and SLC39A confirmed roles for
these genes in regulating plasma levels of cholesterol
and triglycerides, respectively. Moreover, hepatic
DGAT2 merits further attention as a parallel, or pos-
sibly alternative, drug target to DGAT1 for improving
insulin resistance and reducing body weight.
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